The EU Commission clears a merger subject to remedies in the biotechnologies market (Danaher / GE Healthcare Life Sciences’ Biopharma Business)

Mergers: Commission approves Danaher's acquisition of GE Healthcare Life Sciences' Biopharma Business, subject to conditions* The European Commission has approved, under the EU Merger Regulation, the proposed acquisition of General Electric's Healthcare Life Sciences Biopharma Business by Danaher Corporation. The approval is conditional on the divestiture of a remedy package. Executive Vice-President Margrethe Vestager, in charge of competition policy, said: “The bioprocessing industry has brought us new medicines to treat diseases affecting many people, such as cancer, rheumatoid arthritis and multiple sclerosis. To develop and produce these medicines, the bioprocessing industry relies on instruments and consumables supplied by GE and Danaher, amongst others. Danaher offered to

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

European Commission, The EU Commission clears a merger subject to remedies in the biotechnologies market (Danaher / GE Healthcare Life Sciences’ Biopharma Business), 18 December 2019, e-Competitions Bulletin December 2019, Art. N° 92810

Visites 204

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues